date,title,source
Oct-23-18,Imprimis Pharmaceuticals Subsidiary Melt Pharmaceuticals Initiates Clinical Development Program for its Patented Non-Opioid and Non-Invasive MK Melt Conscious Sedation Drug Candidate,GlobeNewswire
Nov-06-18,"Imprimis Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 13, 2018",GlobeNewswire
